NA-Selank vs Semax
A side-by-side research comparison of NA-Selank and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | NA-Selank | Semax |
|---|---|---|
| Full name | N-Acetyl Selank (Acetylated Selank) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Same tuftsin-derived mechanism as Selank with acetyl group providing protease resistance; modulates GABA, enhances BDNF. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | 793.91 Da | 813.9 Da |
| Half-life | ~5-10 minutes (effective 4-6 hours) | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | ~95% intranasal | Moderate (intranasal) |
| Typical dose | 200-400 mcg | 200-600 mcg per dose |
| Frequency | 1-2x daily | 2-3x daily |
| Route | Intranasal spray | Intranasal drops/spray |
NA-Selank reported benefits
- Enhanced anxiolytic effect
- Improved stability
- Better bioavailability
- Cognitive focus
- Stress resilience
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.